Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 Sickle Cell Disease Highlights
20 June 2024 | Virtual Meeting
Presentation summaries of key sickle cell disease abstracts from ASCO & EHA 2024.
Latest in curative therapies and disease-modifying agents
Reni-cel, the first ASCAS12A gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the RUBY trial
Rabi Hanna Cleveland Clinic, Cleveland, OH, United States
Azathioprine/hydroxyurea preconditioning prior to non-myeloablative matched sibling donor hematopoietic stem cell transplantation with sickle cell disease: A prospective observational cohort study
Elisabeth Dovern Amsterdam UMC, Amsterdam, Netherlands
Long-term effect of voxelotor on red blood cell transfusions and vaso-occlusive crises in patients with sickle cell disease: Results from an open-label extension of the Phase III HOPE trial
Richard Drachtman Rutgers Cancer Institute, New Brunswick, NJ, United States
Panel Discussion
Implementation of high-quality care
Factors driving participation in clinical trials among people with sickle cell disease differ in importance across geographic regions: findings from the global listen survey
Raffaella Colombatti University of Padova, Padova, Italy
Impact of hydroxyurea on cerebral vasculopathy in children with sickle cell anemia after initiation for frequent crises or severe anemia in absence of abnormal velocities and arterial stenosis
Françoise Bernaudin Intercommunal Hospital of Creteil, Creteil, France
Panel Discussion
